Bone mineral density in glycogen storage disease type Ia and Ib

Genetics in Medicine

Volumn 14, Issue 8, 2012, Pages 737-741

  Minarich, Laurie A ^a   Kirpich, Alexander ^b   Fiske, Laurie M ^a   Weinstein, David A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

complications; glycogen storage disease I; osteopenia; osteoporosis

Indexed keywords

25 HYDROXYVITAMIN D; CORTICOSTEROID; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORTICOSTEROID THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 1; GLYCOGEN STORAGE DISEASE TYPE 1A; GLYCOGEN STORAGE DISEASE TYPE 1B; HUMAN; MALE; MEDICAL RECORD REVIEW; METABOLIC REGULATION; OSTEOPOROSIS; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT DURATION;

EID: 84864690539     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.36     Document Type: Article

References (15)

1. Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord 2003;4:95-102.
2. Beaudet AL, Anderson DC, Michels VV, Arion WJ, Lange AJ. Neutropenia and impaired neutrophil migration in type IB glycogen storage disease. J Pediatr 1980;97:906-910.
3. Gitzelmann R, Bosshard NU. Defective neutrophil and monocyte functions in glycogen storage disease type Ib: a literature review. Eur J Pediatr 1993;152(suppl 1):S33-S38.
4. Roe TF, Thomas DW, Gilsanz V, Isaacs H Jr, Atkinson JB. Inflammatory bowel disease in glycogen storage disease type Ib. J Pediatr 1986;109:55-59.
5. Lee PJ, Patel JS, Fewtrell M, Leonard JV, Bishop NJ. Bone mineralisation in type 1 glycogen storage disease. Eur J Pediatr 1995;154:483-487.
6. Cabrera-Abreu J, Crabtree NJ, Elias E, Fraser W, Cramb R, Alger S. Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX. J Inherit Metab Dis 2004;27:1-9.
7. Rake JP, Visser G, Huismans D, et al. Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study. J Inherit Metab Dis 2003;26:371-384.
8. Schwahn B, Rauch F, Wendel U, Schönau E. Low bone mass in glycogen storage disease type 1 is associated with reduced muscle force and poor metabolic control. J Pediatr 2002;141:350-356.
9. Krieger NS, Sessler NE, Bushinsky DA. Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol 1992;262(3 Pt 2):F442-F448.
10. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-282.
11. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592-5599.
12. Banugaria SG, Austin SL, Boney A, Weber TJ, Kishnani PS. Hypovitaminosis D in glycogen storage disease type I. Mol Genet Metab 2010;99:434-437.
13. Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr 2002;161(suppl 1):S35-S39.
14. Wang DQ, Fiske LM, Carreras CT, Weinstein DA. Natural history of hepatocellular adenoma formation in glycogen storage disease type I. J Pediatr 2011;159:442-446.
15. Martens DH, Rake JP, Navis G, Fidler V, van Dael CM, Smit GP. Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition. Clin J Am Soc Nephrol 2009;4:1741-1746.